Estados Unidos · Bolsas y cotizaciones · Nasdaq

BioNTech, DualityBio Breast Cancer Drug Meets Phase 3 Trial Goal But Shows Higher Lung Disease Rate

Publicado por Nasdaq · Estados Unidos hace 1 h

(RTTNews) - On Monday, BioNTech (BNTX) and DualityBiologics, subsidiary of Duality Biotherapeutics (9606.HK) said trastuzumab pamirtecan met the primary endpoint in the Phase 3…

Leer el artículo completo en Nasdaq Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.nasdaq.com)

BioNTech, DualityBio Breast Cancer Drug Meets Phase 3 Trial Goal But Shows Higher Lung Disease Rate

También te puede interesar

U.S. Army Says It Has Helped 1.5 Billion Barrels of Oil Out of Hormuz

Latest Monero (XMR) Price Analysis

Warren Buffett’s Value Investing Strategy for Wealth: Patience and Quality

Tech Sell-Off Leads to Uptick in Defensive Stocks

Introducing new self-learning context enrichment in Knowledge Catalog

BioNTech, DualityBio Breast Cancer Drug Meets Phase 3 Trial Goal But Shows Higher Lung Disease Rate

Compartir

También te puede interesar

U.S. Army Says It Has Helped 1.5 Billion Barrels of Oil Out of Hormuz

Latest Monero (XMR) Price Analysis

Warren Buffett’s Value Investing Strategy for Wealth: Patience and Quality

Tech Sell-Off Leads to Uptick in Defensive Stocks

Introducing new self-learning context enrichment in Knowledge Catalog